AstraZeneca (AZN.L) is to co-promote Amgen’s (AMGN.O) promising new drug denosumab in Japan as a treatment for bone cancer disorders alongside Daiichi Sankyo (4568.T), boosting its presence in the country.
Japan is a growing focus for Western drugmakers, who see good prospects in the country as more medicines originally developed for U.S. and European markets are introduced.
